Eiko Lifesciences Ltd (EIKO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Eiko Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve 1. The Unaudited Standalone ....
Intimation · 05 Nov 2026, 5:30 am
Eiko LifeSciences Schedules Board Meeting on 5th Nov'26 for Q2 Results Eiko LifeSciences Limited has scheduled its Board of Directors meeting for 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the company confirmed that its insider trading window has been closed since 1st Oct'26 and will remain shut for designated persons and their immediate relatives until 48 hours following the declaration of the financial results.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lenus Finvest Pvt Ltd
Acquisition/ Disposal of Shares · 19 Oct 2026, 4:13 pm
Lenus Finvest Increases Eiko Lifesciences Stake to 18.18% via Warrant Conversion Lenus Finvest Private Limited, a promoter group entity, acquired 1,50,000 equity shares of Eiko Lifesciences Limited on 16th Oct'26 through the conversion of preferential warrants, representing 1.02% of total voting capital. Post-allotment, Lenus Finvest’s aggregate holding increased from 25,40,472 equity shares (17.34%) to 26,90,472 shares, representing 18.18% of non-diluted equity share capital and 15.56% on a fully diluted basis. Consequently, Eiko Lifesciences' total issued equity share capital expanded from 1,46,50,854 shares (Rs 14.65 crore) to 1,48,00,854 shares (Rs 14.80 crore).
Board of Directors of the Company vide Circular Resolution today, i.e. Friday, 16th October, 2026, considered and approved the allotment of equity shares on conversion of 1,50,000 (One ....
Rights Issue · 17 Oct 2026, 1:02 am
Eiko LifeSciences Approves Warrant Conversion and Share Allotment to Promoter Eiko LifeSciences approved the conversion of 1,50,000 warrants into 1,50,000 equity shares at an issue price of Rs. 55 each (including a Rs. 45 premium) to promoter entity Lenus Finvest Private Limited on 16th Oct'26. The allotment followed the receipt of Rs. 61.88 lakh (75% balance issue price). Consequently, Lenus Finvest's stake increased from 17.34% to 18.18%, expanding the company’s paid-up equity share capital to Rs. 14.80 crore across 1,48,00,854 shares, while 24,95,000 warrants remain pending for conversion.
With refrence to the 49th Annual General Meeting of the Company held on Tuesday, 22nd September, 2026 at 04:00 P.M. IST through Video Conference/ Other Audio Visual Means, please find attached ....
Annual General Meeting · 23 Sept 2026, 11:21 pm
The Proceedings of the 49th Annual General Meeting (AGM) of Eiko LifeSciences Limited held on Tuesday, 22nd September, 2026 at 04:00 P.M. IST through Video Conferencing ('VC')/ Other Audio-Visual ....
Annual General Meeting · 23 Sept 2026, 12:24 am
The Company has sent a letter providing the weblink and QR Code for accessing the Notice convening the 49th Annual General Meeting ("AGM") and the Annual Report of the Company for the Financial ....
Annual General Meeting · 27 Aug 2026, 11:58 pm
Pursuant to provision of Regulations 30 and 34 of the SEBI LODR Regulations, 2015, we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday, 22nd day ....
Others (Uncategorized) · 25 Aug 2026, 2:11 am
Pursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the 49th Annual General Meeting of ....
Annual General Meeting · 25 Aug 2026, 1:57 am
The Meeting of the Board of Directors of the Company held today i.e., on Monday, 24th August, 2026, Board, inter-alia, considered the following: 1. Noting of resignation of Ms. Hasti ....
Change in Management · 25 Aug 2026, 1:02 am
Eiko Lifesciences Independent Director Resigns Ms. Hasti Doshi (DIN: 10757758) has resigned from her position as Independent Director of Eiko Lifesciences, effective from the close of business on 24th Aug'26. The resignation, tendered well before her term's scheduled completion on 03rd Sep'29, is attributed to other career commitments. The company has confirmed there are no other material reasons for her departure. Ms. Doshi does not hold directorships in any other listed entities.
Appointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as Additional Director (Independent and Non-Executive) of the Company to hold the office up to the date of the ensuing Annual General ....
Change in Management · 25 Aug 2026, 12:53 am
Meeting of the Board of Directors of the Company held today i.e., on Monday, 24th August, 2026, Board, inter-alia, considered the following: 1. Noting of resignation of Ms. Hasti Doshi ....
Others (Uncategorized) · 24 Aug 2026, 11:16 pm
As per PDF attached.
Others (Uncategorized) · 19 Aug 2026, 12:29 am
Eiko Lifesciences Disputes ₹58 Lakhs Historical Claim, Expects No Material Impact Eiko Lifesciences received recovery proceedings from IDBI Bank regarding an alleged corporate guarantee of ₹58 lakhs. This claim relates to a historical transaction from 1986, nearly four decades ago, involving the company's erstwhile entity, Narendra Investments. The company disputes the claim, has not admitted any liability, and is pursuing all available legal remedies. Based on the facts and legal position, management does not expect any material financial impact on its business operations from this matter.
Disclosure of Conversion of 305000 Warrants into Equity Shares belonging to Promoter and Non Promoter Category
Others (Uncategorized) · 18 Aug 2026, 8:25 pm
Eiko Lifesciences: Warrant Conversion Increases Promoter & Non-Promoter Equity Eiko Lifesciences' board approved the conversion of 305,000 warrants into equity shares on 18th Aug'26 for Promoter and Non-Promoter entities. The conversion occurred at an issue price of Rs. 55 per share upon receipt of the final 75% payment (Rs. 1.25 Cr). Promoter Bhavesh Tanna's stake increased from 5.86% to 6.62%. Consequently, paid-up capital rose to Rs. 14.65 Cr. Post-conversion, 22,45,000 warrants from the same allottees remain outstanding.
Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments ....
Outcome · 12 Aug 2026, 7:18 pm
Eiko Lifesciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 1,675 (+56.4% YoY | -8.7% QoQ) ■ EBITDA: 194 (+28.2% YoY | -15.2% QoQ) ■ EBITDA Margin (%): 11.6 (-254 bps YoY | -90 bps QoQ) ■ PAT: 131 (+43.1% YoY | +0.6% QoQ) ■ EPS (INR): 0.76 (+15.2% YoY | -11.6% QoQ) Eiko Lifesciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) Segmental Performance Specialty & Fine Chemicals ■ Revenue: 1,525 (+81.5% YoY | -9.7% QoQ) ■ EBIT: 98.9 (+122.6% YoY | -21.1% QoQ) ■ EBIT Margin (%): 6.5 (+119 bps YoY | -94 bps QoQ) Logistics Business ■ Revenue: 150 (-35.2% YoY | +2.7% QoQ) ■ EBIT: 28.7 (-3.6% YoY | -0.9% QoQ) ■ EBIT Margin (%): 19.2 (+630 bps YoY | -70 bps QoQ)
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve The Unaudited Standalone ....
Intimation · 12 Aug 2026, 5:30 am
Eiko Lifesciences Board Meeting Scheduled to Approve Q1FY27 Results Eiko Lifesciences has scheduled a Board of Directors meeting on 12th Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30th Jun'26. In connection with this, the trading window for designated persons has been closed from 01st Jul'26 and will reopen 48 hours after the financial results are declared. This action complies with Regulation 29 of the SEBI (LODR) Regulations, 2015.
Re-appointment of M/s NP Rajput & Co as Internal Auditor for FY 2026-27, at the Board Meeting held on 26th May, 2026.
Change in Management · 26 May 2026, 7:44 pm
Eiko Lifesciences Re-appoints Internal Auditor for FY 2026-27 Eiko Lifesciences' Board of Directors, based on Audit Committee recommendations, has approved the re-appointment of M/s NP Rajput & Co as the company's Internal Auditor. The appointment, effective from 26th May'26, is for the financial year 2026-27. M/s NP Rajput & Co possesses extensive experience in internal audit, GST compliance, and accounting. The company confirmed no relationship exists between the newly appointed auditor and its directors. This is a routine governance update ensuring continuity in internal controls and financial oversight.
Audited Financial Results (Standalone and Consolidated) for quarter and year ended 31st March, 2026
Outcome · 26 May 2026, 6:57 pm
Eiko Lifesciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 1,834 (+62.7% YoY | +53.0% QoQ) ■ EBITDA: 229 (+74.1% YoY | +21.8% QoQ) ■ EBITDA Margin (%): 12.5 (+81 bps YoY | -319 bps QoQ) ■ PAT: 130 (+24.4% YoY | +7.8% QoQ) ■ EPS (INR): 0.86 (+7.5% YoY | -2.3% QoQ) Eiko Lifesciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) Segmental Performance Speciality Chemicals & Pharma Intermediates ■ Revenue: 1,688 (+132.4% YoY | +61.0% QoQ) ■ EBIT: 125 (+246.0% YoY | +53.8% QoQ) ■ EBIT Margin (%): 7.4 (+244 bps YoY | -35 bps QoQ) Logistics Services ■ Revenue: 146 (-63.6% YoY | -2.6% QoQ) ■ EBIT: 28.9 (-2.6% YoY | -9.6% QoQ) ■ EBIT Margin (%): 19.9 (+1245 bps YoY | -154 bps QoQ)
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve The Audited Standalone and ....
Intimation · 26 May 2026, 5:30 am
Eiko Lifesciences Board to Approve Q4 & FY26 Results on 26-May-26 Eiko Lifesciences (BSE: 540204) has scheduled a Board of Directors meeting on 26-May-26 to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended 31-Mar-26. The trading window for designated persons has been closed since 01-Apr-26 and will reopen 48 hours after the results are declared. This meeting is a key event for assessing the company's full-year performance and Q4 results, which will influence near-term stock sentiment.
In view of SEBI circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018 and amendments thereto (the said Circular), we wish to inform you that as on 31st March, 2026, Eiko Lifesciences ....
Others (Uncategorized) · 09 Apr 2026, 11:57 pm
Eiko Lifesciences Not Classified as a Large Corporate by SEBI Eiko Lifesciences (BSE: 540204) announced on 09 Apr'26 that it does not meet the criteria to be classified as a "Large Corporate" as of 31 Mar'26, per SEBI regulations. Consequently, the company is not subject to the mandatory framework for fundraising via debt securities applicable to Large Corporates. Therefore, the requirement to file initial and annual disclosures under this framework does not apply to Eiko Lifesciences.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavesh Dhirajlal Tanna
Acquisition/ Disposal of Shares · 26 Feb 2026, 8:57 pm
Eiko Lifesciences Promoter Increases Stake via Preferential Allotment Promoter Bhavesh Dhirajlal Tanna acquired 4,50,000 equity shares and 15,50,000 convertible warrants of Eiko Lifesciences on a preferential basis on 24th Feb'26. The share acquisition increased his holding from 2.84% to 5.86% on a non-diluted basis. Following the allotment, his total shareholding stands at 8,40,000 shares. Upon full conversion of all allotted warrants, his aggregate stake would further increase to 23,90,000 shares, representing 13.82% of the company's diluted equity share capital.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lenus Finvest Pvt Ltd
Acquisition/ Disposal of Shares · 26 Feb 2026, 5:45 pm
Eiko Lifesciences: Promoter Group Entity Increases Stake via Preferential Allotment Promoter group entity Lenus Finvest Private Limited increased its stake in Eiko Lifesciences Ltd on 24th Feb'26 via a preferential allotment. Lenus Finvest acquired 175,000 equity shares (1.22%) and 150,000 convertible warrants. Post-acquisition, its holding increased from 17.24% to 17.71% on a non-diluted basis. Upon full conversion of all warrants, the aggregate promoter holding will stand at 26,90,472 shares, representing a 15.56% stake on a fully diluted basis.
Allotment of 6,25,000 Equity Shares and 29,50,000 Warrants on preferential basis under SEBI (ICDR) Regulations, 2018 through Circulation on Tuesday, 24th February, 2026
Others (Uncategorized) · 24 Feb 2026, 10:11 pm
Eiko LifeSciences Board Approves Preferential Allotment of Shares and Warrants On 24th Feb'26, Eiko LifeSciences' board approved a preferential issue. This includes allotting 6.25 lakh equity shares at Rs. 55 per share, raising Rs. 3.44 cr, primarily to promoter groups. Additionally, 29.5 lakh warrants, convertible into equity shares at Rs. 55 each, were allotted to both promoter and non-promoter entities. This warrant issue raises an initial Rs. 4.06 cr (25% of the total potential Rs. 16.23 cr). The newly issued shares will rank pari-passu with existing equity shares.
Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, ....
Outcome · 29 Jan 2026, 6:39 pm
EIKO LIFESCIENCES LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 1198 (+60.0% YoY | +2.7% QoQ) ■ EBITDA: 188 (+196.1% YoY | +6.3% QoQ) ■ EBITDA Margin (%): 15.7 (+719 bps YoY | +53 bps QoQ) ■ PAT: 121 (+196.0% YoY | +12.2% QoQ) ■ EPS (INR): 0.88 (+175.0% YoY | +12.8% QoQ) EIKO LIFESCIENCES LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) Segmental Performance Speciality Chemicals & Pharma Intermediates ■ Revenue: 1049 (+41.6% YoY | +2.3% QoQ) ■ EBIT: 81.5 (+85.5% YoY | +12.9% QoQ) ■ EBIT Margin (%): 7.8 (+184 bps YoY | +73 bps QoQ) Logistics Services ■ Revenue: 149 (+1774.9% YoY | +5.3% QoQ) ■ EBIT: 32.0 (+433.2% YoY | +4.5% QoQ) ■ EBIT Margin (%): 21.4 (-5387 bps YoY | -16 bps QoQ)
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 ,inter alia, to consider and approve Unaudited standalone and ....
Intimation · 29 Jan 2026, 5:30 am
Eiko Lifesciences Board Meeting on 29th Jan'26 for Q3 Results Eiko Lifesciences has scheduled a Board of Directors meeting on 29th Jan'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended 31st Dec'25. The trading window for designated persons has been closed from 01st Jan'26 and will remain closed until 48 hours after the results are declared. This action is in compliance with SEBI's Regulation 29 (Listing Obligations and Disclosure Requirements).
Combined e-voting results along with Scrutinizer Report.
Extra Ordinary General Meeting · 09 Jan 2026, 7:18 pm
Eiko Lifesciences Shareholders Approve Preferential Issues of Warrants and Equity At its EOGM on 07-Jan'26, Eiko Lifesciences shareholders passed two special resolutions with near-unanimous approval from public non-institutional investors. The resolutions authorize the preferential issuance of 3,300,000 convertible warrants and 675,000 equity shares to both promoter and non-promoter groups. Both proposals received 99.9999% of votes in favour from public shareholders who participated in the e-voting process. The promoter group, being an interested party, had its votes considered invalid for the final resolution results.